Pliant Therapeutics to Join Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 – Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company known for its work in developing therapies for fibrotic diseases, has announced its participation in several investor events in September.

Pliant Therapeutics will be represented at the following conferences:

1. 2024 Wells Fargo Healthcare Conference: Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D., Chief Medical Officer, will be featured in a discussion on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.

2. H.C. Wainwright 26th Annual Global Investment Conference: Both Keith Cummings, M.D. and Éric Lefebvre, M.D., will join a fireside chat on Wednesday, September 11, 2024, at 10:30 a.m. Eastern Time.

3. 2024 Cantor Global Healthcare Conference: President and Chief Executive Officer Bernard Coulie, M.D., Ph.D., along with Keith Cummings, M.D., and Éric Lefebvre, M.D., will participate in a conversation on Tuesday, September 17, 2024, at 10:20 a.m. Eastern Time.

4. Stifel 2024 Virtual Immunology and Inflammation Summit: Bernard Coulie, M.D., Ph.D., and Keith Cummings, M.D. will speak in a discussion on Wednesday, September 18, 2024, at 11:00 a.m. Eastern Time.

Interested participants can join the live webcasts of these sessions by visiting the Investor Relations’ Events & Presentation page on Pliant’s website. The webcasts will be available for replay on the website for 30 days after the events.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a biopharmaceutical company focused on developing innovative therapies for fibrotic diseases. The company’s lead product candidate is bexotegrast (PLN-74809), an oral, small molecule that functions as a dual selective inhibitor of the αvß6 and αvß1 integrins. Bexotegrast is currently being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The U.S. Food and Drug Administration (FDA) has granted bexotegrast Fast Track and Orphan Drug Designations for both IPF and PSC. Similarly, the European Medicines Agency has given bexotegrast Orphan Drug Designation for IPF and PSC. Pliant has commenced the BEACON-IPF trial, an adaptive Phase 2b/3 study of bexotegrast in IPF.

Pliant is also progressing with its third clinical program, PLN-101095, which is a small molecule that selectively inhibits the αvß8 and αvß1 integrins. This program is aimed at treating solid tumors and is currently in Phase 1 trials. Additionally, the company has received regulatory clearance to conduct a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1, which is being developed for the treatment of muscular dystrophies. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!